We are live on ! Find out more
MAIA icon

MAIA Biotechnology
MAIA

22 hedge funds and large institutions have $958K invested in MAIA Biotechnology in 2023 Q4 according to their latest regulatory filings, with 9 funds opening new positions, 9 increasing their positions, 1 reducing their positions, and 1 closing their positions.

New
Increased
Maintained
Reduced
Closed

800% more first-time investments, than exits

New positions opened: 9 | Existing positions closed: 1

800% more repeat investments, than reductions

Existing positions increased: 9 | Existing positions reduced: 1

57% more funds holding

Funds holding: 14 → 22 (+8)

37% more capital invested

Capital invested by funds: $700K → $958K (+$258K)

2.42% more ownership

Funds ownership: 2.33% → 4.74% (+2.4%)

Holders
22
Holders Change
+8
Holders Change %
+57.14%
% of All Funds
0.32%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
9
Increased
9
Reduced
1
Closed
1
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
SM
Sabby Management
Florida
+$211K
2
Renaissance Technologies
Renaissance Technologies
New York
+$179K
3
Vanguard Group
Vanguard Group
Pennsylvania
+$130K
4
Citadel Advisors
Citadel Advisors
Florida
+$92.8K
5
BCM
Bridgeway Capital Management
Texas
+$38.9K

Top Sellers

Rank Fund Capital Flow
1
FIA
FNY Investment Advisers
New York
-$38K
2
TRCT
Tower Research Capital (TRC)
New York
-$2.15K

MAIA Hedge Fund Activity: Q4 2023 in Review

22 of the 6,870 institutional investors tracked by Wall St. Rank reported a position in MAIA Biotechnology (MAIA) for Q4 2023, worth a combined $958K — up 37% from $700K a quarter earlier.

Buyers outnumbered sellers: 9 funds opened new MAIA positions and 1 closed out — a net gain of 8 holders — while 9 added to existing stakes and 1 trimmed.

The largest buyer was Sabby Management, opening a new position worth an estimated $211K. The largest seller was FNY Investment Advisers, exiting entirely with an estimated $38K sold.

  • 22 institutional investors held MAIA Biotechnology (MAIA) as of Q4 2023, up from 14 in Q3 2023.
  • Funds reported $958K of MAIA Biotechnology stock for Q4 2023, up 37% quarter-over-quarter.
  • 9 funds opened new MAIA Biotechnology positions in Q4 2023 and 1 closed out, a net change of +8 holders.
  • The largest MAIA Biotechnology buyer in Q4 2023 was Sabby Management, an estimated $211K added.
  • The largest MAIA Biotechnology seller in Q4 2023 was FNY Investment Advisers, an estimated $38K sold.

Based on aggregated 13F filings for Q4 2023.